Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 7/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664740 | 0.83 | MAPT (0.64) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL6951600 | 0.80 | MAPT (0.60) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL29851934 | 0.80 | MAPT (0.60) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL10597685 | 0.80 | MAPT (0.60) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL14759038 | 0.80 | MAPT (0.60) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL3533968 | 0.80 | KMT2A (0.60) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL3407787 | 0.80 | MAPT (0.60) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL13931173 | 0.80 | KMT2A (0.59) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL11501543 | 0.78 | MAPT (0.59) | MAPTKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL4661873 | 0.78 | MAPT (0.57) | MAPTKMT2AALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | NOBELPHARMA CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| CN-112118839-A | Pyrazolone derivative-containing drug | 耐贝医药株式会社 | 2020-12-22 | — | — | CN | disclosed |
| EP-3666270-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | Nobelpharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-1793821-B1 | PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-3321255-A1 | NOVEL THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) OR DISEASE ATTRIBUTABLE TO ALS | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| US-20170273949-A1 | AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9259416-B2 | Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8183206-B2 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1437137-B1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-12-31 | — | — | EP | disclosed |
| WO-2006016707-A2 | PYRAZOLONE COMPOUNDS FOR TREATING CEREBROVASCULAR DISORDERS | MITSUBISHI PHARMA CORPORATION (JP) | 2006-02-16 | — | — | WO | disclosed |
| EP-1582517-A1 | BLOOD-BRAIN BARRIER DISRUPTION INHIBITORS | Mitsubishi Pharma Corporation (JP) | 2005-10-05 | — | — | EP | disclosed |
| EP-1553087-A1 | PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES | Mitsubishi Pharma Corporation (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-RE35801-E | PYRAZOLONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273949-A1 | AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES | MITF, EYA3, AQP1 | MAPT 2342/4885KMT2A 2873/4885ALDH1A1 344/4885 |
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | ADRB3, TNNI3, AGTR1 | MAPT 4769/4885KMT2A 3473/4885ALDH1A1 662/4885 |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | PLAT, PTGIS, SERPINC1 | MAPT 4680/4885KMT2A 2884/4885ALDH1A1 288/4885 |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | CYP11B2, CYP3A5, DPYD | MAPT 4271/4885KMT2A 1306/4885ALDH1A1 285/4885 |
| US-10004720-B2 | Agent for preventing and/or treating ophthalmologic diseases | MITF, EYA3, AQP1 | MAPT 2342/4885KMT2A 2873/4885ALDH1A1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.